Loading
Life sciences · Journal article
Frontiers in Microbiology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Akkermansia muciniphila ( A. muciniphila ) was isolated and identified about two decades ago. It has drawn great attention due to its close association with diseases, such as obesity, diabetes, inflammatory bowel disease (IBD), liver steatosis, asthma and cardiovascular diseases. Research on the biological functions of A. muciniphila in human diseases has made it a potential probiotic with several therapeutic properties: it helps maintain gut barrier function, reduce brain atrophy, release inflammatory responses, and improve bone health. Its abundance and activity, however, are shaped by a complex interplay of environmental and host factors, including diet, medication, oxygen, bile acids, and microbial interactions. Here we review the genotypic diversity of A. muciniphila and its involvement in oral, atopic, respiratory, intestinal, metabolic, cardiovascular, rheumatic, skeletal, and neurological diseases, with particular attention to its bioactive components—such as the outer membrane protein Amuc_1100, extracellular vesicles, and the GLP-1-inducing protein P9—and the mechanisms through which they act. We also weigh the evidence that, in certain host contexts or in the presence of specific pathogens, A. muciniphila may aggravate rather than alleviate disease. A clearer, strain-level understanding of these context-dependent effects will be essential if A. muciniphila is to move from a promising commensal to a safe and effective therapy. The isolation, identification of A. muciniphila strains with beneficial effects and the large-scale industrial production challenges the translational applications.